# Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

> **NCT02430480** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 39 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Goserelin
- **DRUG:** Enzalutamide
- **DEVICE:** mpMRI

## Key facts

- **NCT ID:** NCT02430480
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-03
- **Primary completion:** 2019-12-01
- **Final completion:** 2024-06-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02430480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02430480, "Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02430480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*